Gland Pharma (GLAND.NS)

Executive Summary

Gland Pharma is a leading pure-play injectable pharmaceutical company and CDMO, headquartered in Hyderabad, India. The company has established a strong global footprint by supplying complex sterile injectables to over 60 countries, with regulatory approvals from the US FDA, UK MHRA, and other stringent authorities. Leveraging its robust manufacturing capabilities and diversified product portfolio (134 commercial products), Gland Pharma has consistently delivered strong financial performance, driven by increasing demand for injectables and CDMO services. The company's focus on high-value, complex generics and strategic partnerships positions it well for sustained growth in the global injectables market, which is projected to expand at a healthy CAGR. Despite near-term headwinds from pricing pressures and raw material costs, Gland Pharma's strong balance sheet and operational efficiency support its long-term value creation.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of One or More Key Injectable Products (e.g., Complex Generics)70% success
• Q4 2026Significant CDMO Contract Win with a Large Global Pharma60% success
• Q2 2027Capacity Expansion at Existing Facilities or New Facility Commissioning80% success